Financial Consequences of The Performance of A Pd-L1 Test To Select Patients Receiving Second and Third Line Treatments for Non-Small Cell Lung Cancer in Italy
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.154
https://www.valueinhealthjournal.com/article/S1098-3015(17)30488-6/fulltext
Section Title :
Disease-Specific Studies
Section Order :
134
First Page :
A424
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30488-6&doi=10.1016/j.jval.2017.08.154